{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:09:31Z","timestamp":1786118971464,"version":"build-2736575974"},"reference-count":81,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,10]]},"DOI":"10.1097\/wco.0b013e32830efc03","type":"journal-article","created":{"date-parts":[[2008,9,3]],"date-time":"2008-09-03T07:04:35Z","timestamp":1220425475000},"page":"555-562","source":"Crossref","is-referenced-by-count":18,"title":["Intravenous immunoglobulins in the treatment of immune neuropathies"],"prefix":"10.1097","volume":"21","author":[{"given":"Bernd C","family":"Kieseier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerd","family":"Meyer zu H\u00f6rste","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helmar C","family":"Lehmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf","family":"Gold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Peter","family":"Hartung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-8-20210206","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1097\/01.wco.0000245365.51823.72","article-title":"Immune circuitry in the peripheral nervous system","volume":"19","author":"Kieseier","year":"2006","journal-title":"Curr Opin Neurol"},{"key":"R2-8-20210206","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/mus.20893","article-title":"The immunocompetence of Schwann cells","volume":"37","author":"Meyer zu Horste","year":"2008","journal-title":"Muscle Nerve"},{"key":"R3-8-20210206","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1097\/01.wco.0000245364.51823.3b","article-title":"The inflamed peripheral nervous system: update on immune therapies","volume":"19","author":"Kieseier","year":"2006","journal-title":"Curr Opin Neurol"},{"issue":"Suppl 5","key":"R4-8-20210206","doi-asserted-by":"crossref","first-page":"V59","DOI":"10.1007\/s00415-006-5008-9","article-title":"Therapy of immune neuropathies with intravenous immunoglobulins","volume":"253","author":"Gold","year":"2006","journal-title":"J Neurol"},{"key":"R5-8-20210206","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/ncpneuro0452","article-title":"From bench to bedside: experimental rationale for immune-specific therapies in the inflamed peripheral nerve","volume":"3","author":"Meyer zu Horste","year":"2007","journal-title":"Nat Clin Pract Neurol"},{"key":"R6-8-20210206","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1097\/00019052-200210000-00013","article-title":"Animal models of immune-mediated neuropathies","volume":"15","author":"M\u00e4urer","year":"2002","journal-title":"Curr Opin Neurol"},{"key":"R7-8-20210206","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1212\/WNL.56.1.74","article-title":"Sural nerve T-cell receptor Vbeta gene utilization in chronic inflammatory demyelinating polyneuropathy and vasculitic neuropathy","volume":"56","author":"Bosboom","year":"2001","journal-title":"Neurology"},{"key":"R8-8-20210206","doi-asserted-by":"crossref","first-page":"4375","DOI":"10.4049\/jimmunol.164.8.4375","article-title":"Differential expression of NK T cell V alpha 24J alpha Q invariant TCR chain in the lesions of multiple sclerosis and chronic inflammatory demyelinating polyneuropathy","volume":"164","author":"Illes","year":"2000","journal-title":"J Immunol"},{"key":"R9-8-20210206","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1002\/(SICI)1097-4598(199604)19:4<474::AID-MUS8>3.0.CO;2-9","article-title":"Inflammatory infiltrates in sural nerve biopsies in Guillain-Barr\u00e9 syndrome and chronic inflammatory demyelinating neuropathy","volume":"19","author":"Schmidt","year":"1996","journal-title":"Muscle Nerve"},{"key":"R10-8-20210206","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1007\/s004150200072","article-title":"Gammadelta T cells infiltrating sensory nerve biopsies from patients with inflammatory neuropathy","volume":"249","author":"Winer","year":"2002","journal-title":"J Neurol"},{"key":"R11-8-20210206","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1093\/intimm\/dxh018","article-title":"Accumulation of Valpha7.2-Jalpha33 invariant T cells in human autoimmune inflammatory lesions in the nervous system","volume":"16","author":"Illes","year":"2004","journal-title":"Int Immunol"},{"key":"R12-8-20210206","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S0165-5728(03)00212-1","article-title":"CDR3 spectratyping analysis of the T cell receptor repertoire in Guillain-Barre and Fisher syndromes","volume":"141","author":"Koga","year":"2003","journal-title":"J Neuroimmunol"},{"key":"R13-8-20210206","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1111\/j.1750-3639.1999.tb00231.x","article-title":"Mechanisms of immune regulation in the peripheral nervous system","volume":"9","author":"Gold","year":"1999","journal-title":"Brain Pathol"},{"key":"R14-8-20210206","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0301-0082(00)00045-9","article-title":"Role of integrins in the peripheral nervous system","volume":"64","author":"Previtali","year":"2001","journal-title":"Prog Neurobiol"},{"key":"R15-8-20210206","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1002\/ana.410440406","article-title":"Expression of integrins in experimental autoimmune neuritis and Guillain-Barre syndrome","volume":"44","author":"Previtali","year":"1998","journal-title":"Ann Neurol"},{"key":"R16-8-20210206","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1093\/brain\/awf070","article-title":"Chemokines and chemokine receptors in inflammatory demyelinating neuropathies: a central role for IP-10","volume":"125","author":"Kieseier","year":"2002","journal-title":"Brain"},{"key":"R17-8-20210206","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/S0165-5728(03)00085-7","article-title":"CSF and serum levels of soluble fractalkine (CX3CL1) in inflammatory diseases of the nervous system","volume":"137","author":"Kastenbauer","year":"2003","journal-title":"J Neuroimmunol"},{"key":"R18-8-20210206","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1093\/brain\/121.1.159","article-title":"Matrix metalloproteinase-9 and -7 are regulated in experimental autoimmune encephalomyelitis","volume":"121","author":"Kieseier","year":"1998","journal-title":"Brain"},{"key":"R19-8-20210206","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1212\/WNL.53.1.62","article-title":"Matrix metalloproteinase upregulation in chronic inflammatory demyelinating polyneuropathy and nonsystemic vasculitic neuropathy","volume":"53","author":"Leppert","year":"1999","journal-title":"Neurology"},{"key":"R20-8-20210206","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1097\/00005072-199311000-00001","article-title":"Macrophage systems in peripheral nerves. A review","volume":"52","author":"Griffin","year":"1993","journal-title":"J Neuropathol Exp Neurol"},{"key":"R21-8-20210206","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0301-0082(00)00060-5","article-title":"The role of macrophages in immune-mediated damage to the peripheral nervous system","volume":"64","author":"Kiefer","year":"2001","journal-title":"Prog Neurobiol"},{"key":"R22-8-20210206","first-page":"40","article-title":"Local immune responses in the peripheral nervous system","author":"Hartung","year":"1998"},{"key":"R23-8-20210206","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1002\/mus.20076","article-title":"Advances in understanding and treatment of immune-mediated disorders of the peripheral nervous system","volume":"30","author":"Kieseier","year":"2004","journal-title":"Muscle Nerve"},{"key":"R24-8-20210206","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1093\/brain\/awf272","article-title":"Peripheral neuropathies and antiglycolipid antibodies","volume":"125","author":"Willison","year":"2002","journal-title":"Brain"},{"key":"R25-8-20210206","doi-asserted-by":"crossref","first-page":"11404","DOI":"10.1073\/pnas.0402391101","article-title":"Carbohydrate mimicry between human ganglioside GM1 and Campylobacter jejuni lipooligosaccharide causes Guillain-Barre syndrome","volume":"101","author":"Yuki","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R26-8-20210206","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1002\/ana.1012","article-title":"Animal model of axonal Guillain-Barr\u00e9 syndrome induced by sensitization with GM1 ganliosides","volume":"49","author":"Yuki","year":"2001","journal-title":"Ann Neurol"},{"key":"R27-8-20210206","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1097\/00019052-200210000-00008","article-title":"Acute immunoinflammatory neuropathy: update on Guillain-Barr\u00e9 Syndrome","volume":"15","author":"Hartung","year":"2002","journal-title":"Curr Opin Neurol"},{"key":"R28-8-20210206","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1093\/brain\/awm316","article-title":"Eculizumab prevents antiganglioside antibody-mediated neuropathy in a murine model","volume":"131","author":"Halstead","year":"2008","journal-title":"Brain"},{"key":"R29-8-20210206","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1093\/brain\/awg235","article-title":"Immunoglobulins inhibit pathophysiological effects of anti-GQ1b-positive sera at motor nerve terminals through inhibition of antibody binding","volume":"126","author":"Jacobs","year":"2003","journal-title":"Brain"},{"key":"R30-8-20210206","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1046\/j.1460-9568.1998.00053.x","article-title":"Pre and postsynaptic blockade of neuromuscular transmission by Miller-Fisher syndrome IgG at mouse motor nerve terminals","volume":"10","author":"Buchwald","year":"1998","journal-title":"Eur J Neurosci"},{"key":"R31-8-20210206","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0165-5728(03)00156-5","article-title":"Effects on axonal conduction of antiganglioside sera and sera from patients with Guillain-Barre syndrome","volume":"139","author":"Dilley","year":"2003","journal-title":"J Neuroimmunol"},{"key":"R32-8-20210206","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1002\/mus.10349","article-title":"IgG from patients with Guillain-Barre syndrome interact with nicotinic acetylcholine receptor channels","volume":"27","author":"Krampfl","year":"2003","journal-title":"Muscle Nerve"},{"key":"R33-8-20210206","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1093\/brain\/awn072","article-title":"Complementing the therapeutic armamentarium for Miller Fisher syndrome and related immune neuropathies","volume":"131","author":"Lehmann","year":"2008","journal-title":"Brain"},{"key":"R34-8-20210206","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.autrev.2006.08.011","article-title":"Safety of intravenous immunoglobulin (IVIG) therapy","volume":"6","author":"Katz","year":"2007","journal-title":"Autoimmun Rev"},{"key":"R35-8-20210206","doi-asserted-by":"crossref","first-page":"721","DOI":"10.7326\/0003-4819-126-9-199705010-00008","article-title":"Intravenous immune globulin therapy for neurologic diseases","volume":"126","author":"Dalakas","year":"1997","journal-title":"Ann Intern Med"},{"key":"R36-8-20210206","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/ncpneuro0376","article-title":"Drug insight: the use of intravenous immunoglobulin in neurology: therapeutic considerations and practical issues","volume":"3","author":"Gold","year":"2007","journal-title":"Nat Clin Pract Neurol"},{"key":"R37-8-20210206","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.transci.2007.01.012","article-title":"Intravenous immunoglobulin in autoimmune and inflammatory diseases: more than mere transfer of antibodies","volume":"37","author":"Siberil","year":"2007","journal-title":"Transfus Apher Sci"},{"key":"R38-8-20210206","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1212\/WNL.46.1.100","article-title":"Pilot trial of immunoglobulin versus plasma exchange in patients with Guillain-Barre syndrome","volume":"46","author":"Bril","year":"1996","journal-title":"Neurology"},{"key":"R39-8-20210206","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0140-6736(96)09095-2","article-title":"Randomised trial of plasma exchange, intravenous immuoglobulin, and combined treatments in Guillain-Barre syndrome.","volume":"349","year":"1997","journal-title":"Lancet"},{"key":"R40-8-20210206","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1056\/NEJM199204233261705","article-title":"A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barre syndrome. Dutch Guillain-Barre Study Group","volume":"326","author":"van der Mech\u00e9","year":"1992","journal-title":"N Engl J Med"},{"key":"R41-8-20210206","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1159\/000050777","article-title":"A preliminary, randomized, multicenter study comparing intravenous immunoglobulin, plasma exchange, and immune adsorption in Guillain-Barre syndrome","volume":"46","author":"Diener","year":"2001","journal-title":"Eur Neurol"},{"key":"R42-8-20210206","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1111\/j.1744-9987.1998.tb00124.x","article-title":"Comparative study of efficacy of plasma exchange versus intravenous gammaglobulin treatment on acute postinfectious polyradiculoneuropathy: a preliminary report","volume":"2","author":"Hosokawa","year":"1998","journal-title":"Ther Apher"},{"key":"R43-8-20210206","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1093\/brain\/awm004","article-title":"Immunotherapy for Guillain-Barre syndrome: a systematic review","volume":"130","author":"Hughes","year":"2007","journal-title":"Brain"},{"key":"R44-8-20210206","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/S0140-6736(81)92400-4","article-title":"High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood","volume":"1","author":"Imbach","year":"1981","journal-title":"Lancet"},{"key":"R45-8-20210206","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1136\/jnnp.71.2.235","article-title":"Intravenous immune globulins in patients with Guillain-Barre syndrome and contraindications to plasma exchange: 3 days versus 6 days","volume":"71","author":"Raphael","year":"2001","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R46-8-20210206","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1542\/peds.2004-1324","article-title":"Intravenously administered immunoglobulin in the treatment of childhood Guillain-Barre syndrome: a randomized trial","volume":"116","author":"Korinthenberg","year":"2005","journal-title":"Pediatrics"},{"key":"R47-8-20210206","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1093\/brain\/118.4.841","article-title":"Guillain-Barre syndrome without sensory loss (acute motor neuropathy). A subgroup with specific clinical, electrodiagnostic and laboratory features. Dutch Guillain-Barre Study Group.","volume":"118","author":"Visser","year":"1995","journal-title":"Brain"},{"key":"R48-8-20210206","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/1531-8249(200003)47:3<314::AID-ANA6>3.0.CO;2-C","article-title":"Clinical features and response to treatment in Guillain-Barre syndrome associated with antibodies to GM1b ganglioside","volume":"47","author":"Yuki","year":"2000","journal-title":"Ann Neurol"},{"key":"R49-8-20210206","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/ana.410400209","article-title":"Campylobacter jejuni infections and anti-GM1 antibodies in Guillain-Barre syndrome","volume":"40","author":"Jacobs","year":"1996","journal-title":"Ann Neurol"},{"key":"R50-8-20210206","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1212\/WNL.56.6.758","article-title":"Preceding infections, immune factors, and outcome in Guillain-Barre syndrome","volume":"56","author":"Hadden","year":"2001","journal-title":"Neurology"},{"key":"R51-8-20210206","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/S0140-6736(03)15324-X","article-title":"Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barre syndrome: randomised trial","volume":"363","author":"van Koningsveld","year":"2004","journal-title":"Lancet"},{"key":"R52-8-20210206","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1097\/WCO.0b013e3282ff5b8f","article-title":"Use of intravenous immunoglobulin and plasma exchange in neurological disease","volume":"21","author":"Linker","year":"2008","journal-title":"Curr Opin Neurol"},{"key":"R53-8-20210206","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1056\/NEJMra041347","article-title":"Chronic inflammatory demyelinating polyneuropathy","volume":"352","author":"Koller","year":"2005","journal-title":"N Engl J Med"},{"key":"R54-8-20210206","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1212\/WNL.40.2.209","article-title":"High-dose intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a double-blind, placebo-controlled, crossover study","volume":"40","author":"van Doorn","year":"1990","journal-title":"Neurology"},{"key":"R55-8-20210206","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1093\/brain\/119.4.1067","article-title":"Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy. A double-blind, placebo-controlled, cross-over study","volume":"119","author":"Hahn","year":"1996","journal-title":"Brain"},{"key":"R56-8-20210206","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1002\/ana.410300119","article-title":"Treatment of chronic inflammatory demyelinating polyneuropathy with intravenous immunoglobulin","volume":"30","author":"Cornblath","year":"1991","journal-title":"Ann Neurol"},{"key":"R57-8-20210206","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S1474-4422(02)00222-3","article-title":"Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review","volume":"1","author":"van Schaik","year":"2002","journal-title":"Lancet Neurol"},{"key":"R58-8-20210206","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1093\/brain\/119.4.1055","article-title":"Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy. A double-blind, sham-controlled, cross-over study","volume":"119","author":"Hahn","year":"1996","journal-title":"Brain"},{"key":"R59-8-20210206","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1212\/WNL.56.4.445","article-title":"Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy.","volume":"56","author":"Mendell","year":"2001","journal-title":"Neurology"},{"key":"R60-8-20210206","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1002\/ana.1088","article-title":"Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculopathy","volume":"50","author":"Hughes","year":"2001","journal-title":"Ann Neurol"},{"key":"R61-8-20210206","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1111\/j.1085-9489.2005.10302.x","article-title":"Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy. Report of a Joint Task Force of the European Federation of Neurological Societies and the Peripheral Nerve Society.","volume":"10","year":"2005","journal-title":"J Peripher Nerv Syst"},{"key":"R62-8-20210206","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/S1474-4422(07)70329-0","article-title":"Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial","volume":"7","author":"Hughes","year":"2008","journal-title":"Lancet Neurol"},{"key":"R63-8-20210206","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1212\/WNL.60.8_suppl_3.S8","article-title":"Research criteria for defining patients with CIDP","volume":"60","author":"Sander","year":"2003","journal-title":"Neurology"},{"key":"R64-8-20210206","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S1474-4422(07)70330-7","article-title":"Intravenous immunoglobulin: a first-line treatment in CIDP?","volume":"7","author":"Vermeulen","year":"2008","journal-title":"Lancet Neurol"},{"key":"R65-8-20210206","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1007\/BF00868527","article-title":"A novel trial design to study the effect of intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy","volume":"243","author":"Thompson","year":"1996","journal-title":"J Neurol"},{"key":"R66-8-20210206","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1136\/jnnp.56.1.36","article-title":"Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy: a double blind, placebo controlled study","volume":"56","author":"Vermeulen","year":"1993","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R67-8-20210206","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1212\/WNL.44.3_Part_1.429","article-title":"Intravenous immunoglobulin treatment in patients with motor neuron syndromes associated with anti-GM1 antibodies: a double-blind, placebo-controlled study","volume":"44","author":"Azulay","year":"1994","journal-title":"Neurology"},{"key":"R68-8-20210206","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1212\/WNL.55.9.1256","article-title":"Multifocal motor neuropathy improved by IVIg: randomized, double-blind, placebo-controlled study","volume":"55","author":"Federico","year":"2000","journal-title":"Neurology"},{"key":"R69-8-20210206","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1093\/brain\/124.1.145","article-title":"Intravenous immunoglobulin therapy in multifocal motor neuropathy: a double-blind, placebo-controlled study","volume":"124","author":"Leger","year":"2001","journal-title":"Brain"},{"key":"R70-8-20210206","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1136\/jnnp.59.3.248","article-title":"Treatment of multifocal motor neuropathy with high dose intravenous immunoglobulins: a double blind, placebo controlled study","volume":"59","author":"Van den Berg","year":"1995","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R71-8-20210206","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1002\/1531-8249(200012)48:6<919::AID-ANA13>3.0.CO;2-J","article-title":"Multifocal motor neuropathy: diagnostic criteria that predict the response to immunoglobulin treatment","volume":"48","author":"Van den Berg-Vos","year":"2000","journal-title":"Ann Neurol"},{"key":"R72-8-20210206","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1136\/jnnp.72.6.761","article-title":"Multifocal motor neuropathy: clinical and immunological features and response to IVIg in relation to the presence and degree of motor conduction block","volume":"72","author":"Nobile-Orazio","year":"2002","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R73-8-20210206","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1136\/jnnp.67.1.15","article-title":"Use of human intravenous immunoglobulin in lower motor neuron syndromes","volume":"67","author":"Ellis","year":"1999","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R74-8-20210206","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1002\/(SICI)1097-4598(200006)23:6<900::AID-MUS9>3.0.CO;2-Y","article-title":"Natural history of 46 patients with multifocal motor neuropathy with conduction block","volume":"23","author":"Taylor","year":"2000","journal-title":"Muscle Nerve"},{"key":"R75-8-20210206","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1136\/jnnp.2007.121756","article-title":"Intravenous immunoglobulin as short- and long-term therapy of multifocal motor neuropathy: a retrospective study of response to IVIg and of its predictive criteria in 40 patients","volume":"79","author":"Leger","year":"2008","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R76-8-20210206","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1212\/01.WNL.0000110185.23464.A1","article-title":"How long is IVIg effective in multifocal motor neuropathy?","volume":"62","author":"Terenghi","year":"2004","journal-title":"Neurology"},{"key":"R77-8-20210206","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1007\/s00415-002-0808-z","article-title":"A randomised controlled trial of intravenous immunoglobulin in IgM paraprotein associated demyelinating neuropathy","volume":"249","author":"Comi","year":"2002","journal-title":"J Neurol"},{"key":"R78-8-20210206","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1002\/ana.410400516","article-title":"A controlled study of intravenous immunoglobulin in demyelinating neuropathy with IgM gammopathy","volume":"40","author":"Dalakas","year":"1996","journal-title":"Ann Neurol"},{"key":"R79-8-20210206","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1001\/archneur.59.5.766","article-title":"Efficacy of intravenous immunoglobulin in patients with IgG monoclonal gammopathy and polyneuropathy","volume":"59","author":"Gorson","year":"2002","journal-title":"Arch Neurol"},{"key":"R80-8-20210206","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1007\/s00415-006-0258-0","article-title":"Subcutaneous self-infusions of immunoglobulins as a potential therapeutic regimen in immune-mediated neuropathies","volume":"253","author":"Koller","year":"2006","journal-title":"J Neurol"},{"key":"R81-8-20210206","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1002\/mus.20909","article-title":"Subcutaneous immunoglobulin infusion: a new therapeutic option in chronic inflammatory demyelinating polyneuropathy","volume":"37","author":"Lee","year":"2008","journal-title":"Muscle Nerve"}],"container-title":["Current Opinion in Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/WCO.0b013e32830efc03","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T17:04:37Z","timestamp":1786035877000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00019052-200810000-00008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,10]]},"references-count":81,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.1097\/wco.0b013e32830efc03","relation":{},"ISSN":["1350-7540"],"issn-type":[{"value":"1350-7540","type":"print"}],"subject":[],"published":{"date-parts":[[2008,10]]}}}